Gene Sequencing and In-Vivo - Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Gene Sequencing

In-Vivo

Precision Bio climbs on near-$1.5bn sickle cell pact with Novartis

pharmaphorum

JUNE 23, 2022

Novartis has shouldered its way into the in vivo gene editing category via a deal with US biotech Precision BioSciences, focused on a therapy for sickle cell disease (SCD). Other companies – notably Vertex Pharma/CRISPR Therapeutics and bluebird bio – are taking an ex vivo approach to SCD and thalassaemia and are much closer to market.

Gene Editing

Gene Editing In-Vivo Gene Sequencing Gene

Vertex eyes controllable genetic drugs with $1.3bn Obsidian alliance

pharmaphorum

APRIL 23, 2021

Vertex Pharma has ramped up its involvement in gene-editing medicines for the second time in a week, paying Obsidian Therapeutics $75 million upfront to access its technology platform. . Vertex is also offering up to $1.3 For example, adding a small-molecule might stabilise the medicine, allowing levels of the target protein to increase. .

Gene Editing

Gene Editing Genetics Drugs Gene

Precision Bio climbs on near-$1.5bn sickle cell pact with Novartis

Vertex eyes controllable genetic drugs with $1.3bn Obsidian alliance

Stay Connected